Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma

Abstract Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single‐agent Len may be effective as prolonged treatment regimen in RRMM once patients demonstrate an initial response to Len+Dex induction. Patie...

Full description

Saved in:
Bibliographic Details
Main Authors: Johan Lund, Astrid Gruber, Birgitta Lauri, Adil Doganay Duru, Cecilie Blimark, Agneta Swedin, Markus Hansson, Karin Forsberg, Lucia Ahlberg, Conny Carlsson, Anders Waage, Peter Gimsing, Annette Juul Vangsted, Ulf Frølund, Erik Holmberg, Gösta Gahrton, Evren Alici, Mats Hardling, Ulf‐Henrik Mellqvist, Hareth Nahi
Format: Article
Language:English
Published: Wiley 2018-06-01
Series:Cancer Medicine
Subjects:
Clinical Trial
Lenalidomide
Multiple Myeloma
Online Access:https://doi.org/10.1002/cam4.1422
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.1422

Similar Items